Target intelligence / Profile preview

GATM antisense RNA 1

Molecular classification: Long non-coding RNA (lncRNA), Natural antisense transcript (NAT)

Overview

GATM antisense RNA 1 is a natural antisense transcript (NAT) and a member of the long non-coding RNA (lncRNA) family, transcribed from the strand complementary to the GATM (Glycine amidinotransferase) gene locus. Antisense lncRNAs typically regulate the expression of their associated “sense” genes through a variety of mechanisms, such as blocking transcription, influencing RNA stability, or guiding epigenetic modifications[1][2][3][6]. There is currently no evidence that GATM antisense RNA 1 serves as a therapeutic target, biomarker, or is directly associated with disease or drug action.

Biological functions

Regulation of gene expression (potentially at the level of transcription, splicing, or epigenetic modification)

Beyond the preview

Go deeper on GATM antisense RNA 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GATM antisense RNA 1.

Explore the full profile